Samjin Pharmaceuticals Co., Ltd. (005500.KS)
KRW 18280.0
(-0.33%)
KRW 18280.0
(-0.33%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 79.6 Billion KRW | 16.05% |
| 2022 | 68.59 Billion KRW | -1.6% |
| 2021 | 69.7 Billion KRW | -0.51% |
| 2020 | 70.06 Billion KRW | 20.74% |
| 2019 | 58.03 Billion KRW | -5.98% |
| 2018 | 61.72 Billion KRW | 20.0% |
| 2017 | 51.43 Billion KRW | 21.56% |
| 2016 | 42.31 Billion KRW | -1.72% |
| 2015 | 43.05 Billion KRW | 26.88% |
| 2014 | 33.93 Billion KRW | 19.24% |
| 2013 | 28.45 Billion KRW | 9.2% |
| 2012 | 26.06 Billion KRW | 7.92% |
| 2011 | 24.14 Billion KRW | -3.88% |
| 2010 | 25.12 Billion KRW | 8.04% |
| 2009 | 23.25 Billion KRW | 23.92% |
| 2008 | 18.76 Billion KRW | 47.07% |
| 2007 | 12.75 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 82.99 Billion KRW | 4.26% |
| 2024 Q2 | 85.64 Billion KRW | 3.19% |
| 2023 Q4 | 79.6 Billion KRW | -4.89% |
| 2023 Q1 | 72.9 Billion KRW | 6.29% |
| 2023 Q2 | 76.14 Billion KRW | 4.44% |
| 2023 FY | 79.6 Billion KRW | 16.05% |
| 2023 Q3 | 83.69 Billion KRW | 9.91% |
| 2022 Q4 | 68.59 Billion KRW | -3.95% |
| 2022 Q2 | 68.45 Billion KRW | -2.66% |
| 2022 Q1 | 70.32 Billion KRW | 0.89% |
| 2022 FY | 68.59 Billion KRW | -1.6% |
| 2022 Q3 | 71.41 Billion KRW | 4.32% |
| 2021 Q3 | 62.65 Billion KRW | -9.71% |
| 2021 Q2 | 69.38 Billion KRW | -1.11% |
| 2021 FY | 69.7 Billion KRW | -0.51% |
| 2021 Q1 | 70.16 Billion KRW | 0.14% |
| 2021 Q4 | 69.7 Billion KRW | 11.26% |
| 2020 FY | 70.06 Billion KRW | 20.74% |
| 2020 Q3 | 70.63 Billion KRW | 12.31% |
| 2020 Q4 | 70.06 Billion KRW | -0.8% |
| 2020 Q1 | 59.82 Billion KRW | 3.09% |
| 2020 Q2 | 62.88 Billion KRW | 5.12% |
| 2019 Q4 | 58.03 Billion KRW | -5.43% |
| 2019 Q3 | 61.36 Billion KRW | -3.33% |
| 2019 FY | 58.03 Billion KRW | -5.98% |
| 2019 Q1 | 61.61 Billion KRW | -0.18% |
| 2019 Q2 | 63.47 Billion KRW | 3.03% |
| 2018 Q1 | 52.59 Billion KRW | 2.24% |
| 2018 Q3 | 61.07 Billion KRW | 7.65% |
| 2018 Q2 | 56.73 Billion KRW | 7.88% |
| 2018 Q4 | 61.72 Billion KRW | 1.06% |
| 2018 FY | 61.72 Billion KRW | 20.0% |
| 2017 Q3 | 47.67 Billion KRW | 2.83% |
| 2017 Q2 | 46.36 Billion KRW | 3.03% |
| 2017 Q1 | 44.99 Billion KRW | 6.35% |
| 2017 FY | 51.43 Billion KRW | 21.56% |
| 2017 Q4 | 51.43 Billion KRW | 7.9% |
| 2016 Q1 | 42.68 Billion KRW | -0.86% |
| 2016 Q3 | 40.93 Billion KRW | 1.0% |
| 2016 Q2 | 40.53 Billion KRW | -5.04% |
| 2016 Q4 | 42.31 Billion KRW | 3.36% |
| 2016 FY | 42.31 Billion KRW | -1.72% |
| 2015 FY | 43.05 Billion KRW | 26.88% |
| 2015 Q4 | 43.05 Billion KRW | 3.07% |
| 2015 Q3 | 41.77 Billion KRW | 10.26% |
| 2015 Q2 | 37.88 Billion KRW | 2.43% |
| 2015 Q1 | 36.98 Billion KRW | 9.0% |
| 2014 Q2 | 29.66 Billion KRW | 5.99% |
| 2014 Q3 | 33.18 Billion KRW | 11.89% |
| 2014 FY | 33.93 Billion KRW | 19.24% |
| 2014 Q4 | 33.93 Billion KRW | 2.24% |
| 2014 Q1 | 27.98 Billion KRW | -1.66% |
| 2013 Q3 | 30.04 Billion KRW | 3.81% |
| 2013 Q4 | 28.45 Billion KRW | -5.29% |
| 2013 FY | 28.45 Billion KRW | 9.2% |
| 2013 Q1 | 25.3 Billion KRW | -2.91% |
| 2013 Q2 | 28.94 Billion KRW | 14.39% |
| 2012 Q2 | 20.86 Billion KRW | -13.36% |
| 2012 Q1 | 24.07 Billion KRW | -0.29% |
| 2012 FY | 26.06 Billion KRW | 7.92% |
| 2012 Q4 | 26.06 Billion KRW | 23.69% |
| 2012 Q3 | 21.06 Billion KRW | 0.99% |
| 2011 Q3 | 22.73 Billion KRW | -4.65% |
| 2011 Q4 | 24.14 Billion KRW | 6.2% |
| 2011 FY | 24.14 Billion KRW | -3.88% |
| 2011 Q1 | 19.63 Billion KRW | -21.84% |
| 2011 Q2 | 23.84 Billion KRW | 21.45% |
| 2010 Q4 | 25.12 Billion KRW | 15.93% |
| 2010 Q3 | 21.67 Billion KRW | -16.95% |
| 2010 FY | 25.12 Billion KRW | 8.04% |
| 2010 Q1 | 23.25 Billion KRW | -0.01% |
| 2010 Q2 | 26.09 Billion KRW | 12.23% |
| 2009 Q2 | 26.18 Billion KRW | 19.98% |
| 2009 FY | 23.25 Billion KRW | 23.92% |
| 2009 Q4 | 23.25 Billion KRW | 4.34% |
| 2009 Q3 | 22.28 Billion KRW | -14.9% |
| 2009 Q1 | 21.82 Billion KRW | 16.32% |
| 2008 Q4 | 18.76 Billion KRW | 6.59% |
| 2008 Q2 | 18.97 Billion KRW | 35.9% |
| 2008 Q1 | 13.96 Billion KRW | 9.42% |
| 2008 Q3 | 17.6 Billion KRW | -7.21% |
| 2008 FY | 18.76 Billion KRW | 47.07% |
| 2007 Q1 | 15.18 Billion KRW | 0.0% |
| 2007 FY | 12.75 Billion KRW | 0.0% |
| 2007 Q4 | 12.75 Billion KRW | 9.81% |
| 2007 Q3 | 11.61 Billion KRW | -16.7% |
| 2007 Q2 | 13.94 Billion KRW | -8.17% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -80.292% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 32.455% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 12.684% |
| HANDOK Inc. | 94.46 Billion KRW | 15.733% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -274.723% |
| Yuhan Corporation | 284.75 Billion KRW | 72.046% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 31.562% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -389.602% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 72.438% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -145.808% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -28.964% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -308.7% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -162.887% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -64.648% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -80.292% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -154.804% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -126.296% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -65.397% |
| JW Holdings Corporation | 147.58 Billion KRW | 46.065% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 5.933% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 69.551% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 24.968% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -47.622% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -194.847% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -144.846% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 27.481% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -80.292% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 57.802% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 67.044% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 24.968% |
| Yuhan Corporation | 284.75 Billion KRW | 72.046% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 36.46% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | -28.419% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 69.365% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 24.968% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -61.985% |
| CKD Bio Corp. | 69.08 Billion KRW | -15.229% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 24.244% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | -12.597% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -47.255% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -47.622% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 59.129% |
| Boryung Corporation | 189.8 Billion KRW | 58.061% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -40.067% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -28.964% |
| JW Lifescience Corporation | 23.39 Billion KRW | -240.203% |